Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system - Takeaways - MDSpire

Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system

  • By

  • Jiongrui Cao

  • Li Peng

  • Jin Yang

  • Gang Yin

  • Ping Ke

  • Jifa Zhang

  • Min Su

  • Yun Gao

  • Yuehui Zhang

  • June 17, 2026

  • 0 min

Share

  • 1

    Ipilimumab plus nivolumab combination therapy is linked to significant renal and pancreatic toxicities in non-small cell lung cancer patients.

  • 2

    Disproportionality analysis revealed strong signals for glomerular-predominant renal injuries and pancreatic toxicity associated with the combination therapy.

  • 3

    The study analyzed 2,292 reports, identifying 39 renal and 23 pancreatic events in combination therapy versus 114 and 48 in monotherapy.

  • 4

    Median time-to-onset for renal and pancreatic events in the combination group was 73 and 84 days, respectively.

  • 5

    Findings suggest the need for enhanced clinical vigilance and monitoring strategies for renal and pancreatic toxicities in patients receiving Ipi+Nivo.

Original Source(s)

Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system

  • by Jiongrui Cao, Li Peng, Jin Yang, Gang Yin, Ping Ke, Jifa Zhang, Min Su, Yun Gao, Yuehui Zhang

  • June 17, 2026

Related Content

Epstein–Barr virus-driven immunosuppression in nasopharyngeal carcinoma: a comprehensive review of viral mechanisms, spatial tumor ecosystems, and precision therapeutics

Enhancing skin lesion classification using a Tri-Path Attention Stacked Ensemble architecture with Cohen’s Kappa Proportioned Averaging

Multimodal fusion of EHR and ECG based on deep learning for predicting new-onset coronary heart disease in cancer patients